Physician profile
Monica Pinglo
NPI 1962940809
$1,710.82
in general payments reported to CMS, 2019-2025
21 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.99 · 2021: $199 · 2022: $263 · 2023: $414 · 2024: $432 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $406.03 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $311.40 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.22 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.76 | 2020-2024 | Airsupra |
| Pfizer INC. | $113.09 | 2021-2025 | |
| Exact Sciences Corporation | $112.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $108.16 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $74.78 | 2022-2024 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $37.49 | 2022 | |
| Astellas Pharma US INC | $30.38 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $29.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.93 | 2025 | |
| Saluda Medical Americas, INC. | $23.78 | 2025 | Evoke |
| Ibsa Pharma INC. | $23.51 | 2025 | Flector, Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $22.21 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $21.40 | 2025 | Tlando |
| Sanofi Pasteur INC. | $18.40 | 2023 | |
| Boston Scientific Corporation | $18.19 | 2025 | Ams 700 |
| Phadia US INC. | $15.76 | 2022 | |
| Glaxosmithkline, LLC. | $13.28 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Pinglo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.